Should the U.S. Have Bought More Doses of Pfizer's COVID Vaccine?

Reports emerged recently that the Trump administration turned down an opportunity to secure more doses of Pfizer (NYSE: PFE) and BioNTech's (NASDAQ: BNTX) coronavirus vaccine, BNT162b2. In this Motley Fool Live video recorded on Dec. 9, 2020, Healthcare and Cannabis Bureau Chief Corinne Cardina and Fool.com writer Keith Speights discuss what the government was probably thinking and whether the decision could cause problems in the near future.

Continue reading

Source Fool.com